43/120
1.8 / 5 stars
All 120 Win/Lose results shown below
FATE Roast Me summary
FATE THERAPEUTICS INC (FATE). Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Lose.
Trailing 1 year (4 quarters): 3 wins, 9 lossesLast fetched: 25 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
WinFATE / S&P 125.00% / 15.20% |
LoseFATE / S&P -23.36% / 15.00% |
LoseFATE / S&P FATE unavailable / 50.40% |
| 2026-Q11/3 |
WinFATE / S&P 22.45% / -4.33% |
LoseFATE / S&P -52.64% / 11.30% |
LoseFATE / S&P FATE unavailable / 27.70% |
| 2025-Q40/3 |
LoseFATE / S&P -22.22% / 2.65% |
LoseFATE / S&P -51.24% / 9.00% |
LoseFATE / S&P FATE unavailable / 13.40% |
| 2025-Q31/3 |
WinFATE / S&P 12.50% / 8.12% |
LoseFATE / S&P -46.92% / 4.61% |
LoseFATE / S&P FATE unavailable / 13.45% |
| 2025-Q21/3 |
WinFATE / S&P 41.77% / 10.94% |
LoseFATE / S&P -31.23% / 4.83% |
LoseFATE / S&P FATE unavailable / 10.63% |
| 2025-Q11/3 |
LoseFATE / S&P -52.12% / -4.27% |
WinFATE / S&P 105.85% / 4.98% |
LoseFATE / S&P FATE unavailable / 10.57% |
| 2024-Q40/3 |
LoseFATE / S&P -52.86% / 2.41% |
LoseFATE / S&P -78.55% / 5.25% |
LoseFATE / S&P FATE unavailable / 6.15% |
| 2024-Q31/3 |
WinFATE / S&P 6.71% / 5.89% |
LoseFATE / S&P -87.34% / 5.89% |
LoseFATE / S&P FATE unavailable / 6.11% |
| 2024-Q20/3 |
LoseFATE / S&P -55.31% / 4.28% |
LoseFATE / S&P -89.67% / 5.38% |
LoseFATE / S&P FATE unavailable / 5.12% |
| 2024-Q11/3 |
WinFATE / S&P 96.26% / 10.56% |
LoseFATE / S&P -95.27% / 5.71% |
LoseFATE / S&P FATE unavailable / 5.59% |
| 2023-Q41/3 |
WinFATE / S&P 76.42% / 11.69% |
LoseFATE / S&P -34.03% / 6.81% |
LoseFATE / S&P FATE unavailable / 7.78% |
| 2023-Q31/3 |
LoseFATE / S&P -55.46% / -3.27% |
WinFATE / S&P 53.90% / 7.52% |
LoseFATE / S&P FATE unavailable / -5.03% |
| 2023-Q21/3 |
LoseFATE / S&P -16.49% / 8.74% |
WinFATE / S&P 74.71% / 9.50% |
LoseFATE / S&P FATE unavailable / -8.57% |
| 2023-Q11/3 |
LoseFATE / S&P -43.51% / 7.50% |
WinFATE / S&P 116.83% / 10.77% |
LoseFATE / S&P FATE unavailable / -15.69% |
| 2022-Q41/3 |
LoseFATE / S&P -54.98% / 7.56% |
WinFATE / S&P 72.44% / 11.88% |
LoseFATE / S&P FATE unavailable / -17.99% |
| 2022-Q31/3 |
LoseFATE / S&P -9.56% / -4.88% |
WinFATE / S&P 26.22% / 13.47% |
LoseFATE / S&P FATE unavailable / -1.41% |
| 2022-Q21/3 |
LoseFATE / S&P -36.08% / -16.10% |
WinFATE / S&P 42.18% / 13.71% |
LoseFATE / S&P FATE unavailable / 11.04% |
| 2022-Q11/3 |
LoseFATE / S&P -33.74% / -4.60% |
WinFATE / S&P 57.56% / 15.97% |
LoseFATE / S&P FATE unavailable / 42.23% |
| 2021-Q41/3 |
LoseFATE / S&P -1.28% / 11.03% |
WinFATE / S&P 77.66% / 15.00% |
LoseFATE / S&P FATE unavailable / 96.40% |
| 2021-Q31/3 |
LoseFATE / S&P -31.71% / 0.58% |
WinFATE / S&P 198.12% / 10.77% |
LoseFATE / S&P FATE unavailable / 69.42% |
| 2021-Q21/3 |
LoseFATE / S&P 5.26% / 8.55% |
WinFATE / S&P 263.39% / 6.58% |
LoseFATE / S&P FATE unavailable / 51.81% |
| 2021-Q11/3 |
LoseFATE / S&P -9.33% / 6.17% |
WinFATE / S&P 279.26% / -1.06% |
LoseFATE / S&P FATE unavailable / 7.39% |
| 2020-Q42/3 |
WinFATE / S&P 127.50% / 12.15% |
WinFATE / S&P 194.33% / -3.72% |
LoseFATE / S&P FATE unavailable / -33.42% |
| 2020-Q32/3 |
WinFATE / S&P 16.50% / 8.93% |
WinFATE / S&P 92.26% / -2.04% |
LoseFATE / S&P FATE unavailable / -27.10% |
| 2020-Q22/3 |
WinFATE / S&P 54.48% / 20.54% |
WinFATE / S&P 62.38% / -0.46% |
LoseFATE / S&P FATE unavailable / -27.11% |
| 2020-Q12/3 |
WinFATE / S&P 13.49% / -19.60% |
WinFATE / S&P 66.45% / 3.47% |
LoseFATE / S&P FATE unavailable / -14.75% |
| 2019-Q42/3 |
WinFATE / S&P 26.01% / 9.07% |
WinFATE / S&P 125.32% / 5.36% |
LoseFATE / S&P FATE unavailable / 2.99% |
| 2019-Q31/3 |
LoseFATE / S&P -23.50% / 1.70% |
WinFATE / S&P 132.32% / 5.02% |
LoseFATE / S&P FATE unavailable / 0.21% |
| 2019-Q22/3 |
WinFATE / S&P 15.54% / 4.30% |
WinFATE / S&P 98.15% / 6.64% |
LoseFATE / S&P FATE unavailable / 8.65% |
| 2019-Q12/3 |
WinFATE / S&P 36.94% / 13.65% |
WinFATE / S&P 54.59% / 8.12% |
LoseFATE / S&P FATE unavailable / 14.29% |
| 2018-Q41/3 |
LoseFATE / S&P -21.24% / -13.52% |
WinFATE / S&P 15.44% / 9.05% |
LoseFATE / S&P FATE unavailable / 18.23% |
| 2018-Q31/3 |
WinFATE / S&P 43.65% / 7.71% |
LoseFATE / S&P FATE unavailable / 10.21% |
LoseFATE / S&P FATE unavailable / 19.06% |
| 2018-Q21/3 |
WinFATE / S&P 16.19% / 3.43% |
LoseFATE / S&P FATE unavailable / 9.03% |
LoseFATE / S&P FATE unavailable / 14.46% |
| 2018-Q11/3 |
WinFATE / S&P 59.74% / -0.76% |
LoseFATE / S&P FATE unavailable / 7.68% |
LoseFATE / S&P FATE unavailable / 12.46% |
| 2017-Q41/3 |
WinFATE / S&P 54.29% / 6.64% |
LoseFATE / S&P -6.72% / 7.03% |
LoseFATE / S&P FATE unavailable / 13.82% |
| 2017-Q31/3 |
WinFATE / S&P 22.22% / 4.48% |
LoseFATE / S&P FATE unavailable / 5.68% |
LoseFATE / S&P FATE unavailable / 17.57% |
| 2017-Q20/3 |
LoseFATE / S&P -28.79% / 3.09% |
LoseFATE / S&P FATE unavailable / 4.83% |
LoseFATE / S&P FATE unavailable / 17.74% |
| 2017-Q11/3 |
WinFATE / S&P 81.27% / 6.07% |
LoseFATE / S&P FATE unavailable / 3.67% |
LoseFATE / S&P FATE unavailable / 13.32% |
| 2016-Q41/3 |
LoseFATE / S&P -19.55% / 3.82% |
WinFATE / S&P 81.08% / 2.09% |
LoseFATE / S&P FATE unavailable / 7.05% |
| 2016-Q31/3 |
WinFATE / S&P 83.53% / 3.85% |
LoseFATE / S&P FATE unavailable / 0.20% |
LoseFATE / S&P FATE unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-28
| Metric | FATE total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 132.67% | 20.78% |
| Annualized return | 132.67% | 20.78% |
5Y · 2021-09-01 to 2026-08-28
| Metric | FATE total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -96.79% | 83.14% |
| Annualized return | -49.72% | 12.86% |
10Y · 2016-09-01 to 2026-08-28
| Metric | FATE total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -1.23% | 319.30% |
| Annualized return | -0.12% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-25.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |